Harald graduated from the Medical University of Lübeck/Germany. He has received postgraduate clinical certification in internal medicine and specialized in nephrology and clinical immunology. During his time (1987-1990) as a post-doc at the Institute of Chemical Immunology at the Weizmann Institute of Science/Israel he worked on the role of idiotypic networks in autoimmunity.
After his habilitation at the Ludwig-Maximilians-University in Munich/Germany in 1996, he moved to the pharmaceutical industry. He worked at SmithKline Beecham, GlaxoSmithKline, Baxter, Fresenius Biotech where he held management positions with increasing global R&D responsibility and was a Co-Founder of Apogenix (Heidelberg/Germany) in 2006. Under his leadership as COO/CMO of Apogenix, an innovative platform was discovered and developed, which resulted in an extensive portfolio of immuno-oncological substances. In his scientific work he is focused on questions of autoimmunity and tumor immunology. Harald is passionate about developing new medicines addressing unmet needs of cancer patients and improving their lives. Harald joined SOTIO as Chief Medical Officer in February 2019.